Elizabeth A. Mily is a 30+ year healthcare and financial industry veteran, serving most recently as the Executive Vice President, Strategy & Business Development, at Bristol-Myers Squibb. In this role, she oversaw the company strategy and approach to sourcing external innovation, including all business development activities, strategic partnerships, alliance management, mergers and acquisitions, and the company’s broad equity investing portfolio. Elizabeth was appointed to the position in March 2020. Prior to joining Bristol-Myers Squibb, Elizabeth was a senior member of the Global Healthcare Group at Barclays where she led its Lifesciences investment banking business, including coverage of the BioPharma, Life Science Tools and Diagnostics sectors. Prior to joining Barclays, Elizabeth served as Senior Vice President, Corporate Strategy and Development at Thermo Fisher Scientific. Before Thermo Fisher, Elizabeth spent 16 years at Goldman, Sachs & Co., where she was a Managing Director and senior coverage officer within the Healthcare Department of the Investment Banking Division. Elizabeth holds a Master of Science in Foreign Service from Georgetown University and a Bachelor of Arts in German Literature and European History from the Ohio State University. She was also a Fulbright scholar to the Universities of Cologne and Hamburg, Germany and a Congress-Bundestag scholar in Bonn prior to University. Elizabeth serves as a director of Solventum Corporation (NYSE: SOLV), including membership on the Audit and Quality, Science & Technology Committees. She is a director of Ampersand Biomedicines, a private Flagship Pioneering portfolio company.

Sylvia is an experienced biotech industry professional with over ten years of experience in the sector. Prior to joining the T1D fund, she was a Principal on the investment team at Omega Funds, where she focused on early stage investments and company creation across various therapeutic areas including neurology, immunology and rare diseases. She also served as a Board observer for Vanqua Bio, Aerium Therapeutics and Rectify Pharma.

Prior to Omega Funds, Sylvia spent almost 7 years at Ra Pharmaceuticals, a peptide drug discovery company focused on rare diseases associated with complement dysregulation. At Ra, she was involved in the early development of the company’s discovery platform, as well as developing preclinical and translational models for first-in-human studies of its lead product, Zilucoplan, which was recently approved in various countries for generalized myasthenia gravis (gMG). She also provided scientific leadership for multiple discovery programs within the company’s internal pipeline and in collaboration with Merck.

Sylvia earned her Ph.D in Biochemistry Summa Cum Laude from the University Pierre-and-Marie-Curie in Paris, France, while being a full-time visiting fellow in the Department of Genetics at Harvard University where she worked in synthetic biology. She holds an M.S. from Pierre-and-Marie-Curie University in Paris, France and a B.S. in Biochemistry from Joseph-Fourier University in Grenoble, France.